Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP) is a pharmaceutical company focused on the development of novel therapeutics and delivery technologies for the treatment of ocular diseases. The company is led by experienced, world-renowned, clinician scientists with proven ability to bring products to the market. Our lead clinical program, OHR-102 (Squalamine) eye drops, is a novel anti-angiogenic product that provides a non-invasive therapy which in Phase II studies has been shown to improve visual outcomes compared to the current gold standard treatments without requiring additional injections. We are evaluating OHR-102 eye drops, given in combination with Lucentis® (Genentech/Roche) intravitreal injections, for the treatment of retinal diseases including wet age related macular degeneration (AMD), retinal vein occlusion and diabetic retinopathy. Wet AMD is the leading cause of vision loss in the elderly, affecting over 1.75 million patients in the United States alone, and the incidence is expected to dramatically increase in the upcoming years. Data from a Phase II clinical trial in wet AMD demonstrated a positive and clinically meaningful treatment effect of OHR-102 combination therapy and the pivotal Phase III program is being initiated.
Our preclinical pipeline is robust and focused on the development of sustained release therapeutics for ocular diseases utilizing our patented microfabrication platform technology. We currently have several active programs evaluating molecules and approaches for the treatment of primary open angle glaucoma, steroid-induced glaucoma, ocular allergies, and retinal diseases. These programs have been identified by Ohr as large markets of unmet medical need or where sustained release therapeutics can greatly improve upon the way ocular disease is currently being treated, including increasing compliance rates and reducing treatment burden
The promise shown by Ohr Pharmaceutical's product pipeline offers a new ray of hope for patients suffering from numerous blinding ocular diseases, and Ohr’s world-class expertise surrounding the treatment of eye disorders is the key to advancing existing and future pipeline products.